Bill Lundberg
Chief Executive Officer chez MERUS N.V.
Fortune : 7 M $ au 31/03/2024
Profil
Sven Ante Lundberg is currently the President, CEO & Executive Director at Merus NV since 2019.
He is also a Director at Q32 Bio, Inc. (Massachusetts) and Q32 Bio, Inc. Additionally, he serves as an Independent Director at Vor Biopharma, Inc. since 2019.
Previously, Dr. Lundberg worked as a Medical Director at Wyeth LLC and Genzyme Corp.
He was also the Director & Chief Medical Officer at Taligen Therapeutics, Inc. from 2010 to 2012.
He held the position of Vice President & Head-Translational Medicine at Alexion Pharmaceuticals, Inc. from 2011 to 2015.
Dr. Lundberg was the Chief Scientific Officer at CRISPR Therapeutics AG from 2015 to 2018.
He has also held positions as a Principal at Antisoma Research Ltd.
and Antisoma, Inc., as well as Vice President-Clinical Development at Sarossa Capital Ltd.
Dr. Lundberg was a Director at the Alliance for Regenerative Medicine.
Dr. Lundberg's education includes an undergraduate degree from the Massachusetts Institute of Technology, an MBA from the University of Massachusetts, a doctorate from Stanford University School of Medicine, and an MBA from The Isenberg School of Management.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
MERUS N.V.
0,26% | 15/03/2024 | 152 071 ( 0,26% ) | 7 M $ | 31/03/2024 |
VOR BIOPHARMA, INC.
0,04% | 26/03/2024 | 29 432 ( 0,04% ) | 69 754 $ | 31/03/2024 |
0,00% | 25/03/2024 | 67 ( 0,00% ) | 1 142 $ | 31/03/2024 |
Postes actifs de Bill Lundberg
| Sociétés | Poste | Début |
|---|---|---|
| MERUS N.V. | Chief Executive Officer | 31/12/2019 |
| VOR BIOPHARMA INC. | Director/Board Member | 01/03/2019 |
Q32 Bio, Inc.
 Q32 Bio, Inc. BiotechnologyHealth Technology Q32 Bio develops immunomodulatory therapies with protein based molecules using a platform. The company was founded by Shelia Violette and is headquartered in Cambridge, MA. | Director/Board Member | - |
Anciens postes connus de Bill Lundberg
| Sociétés | Poste | Fin |
|---|---|---|
| CRISPR THERAPEUTICS AG | Chief Tech/Sci/R&D Officer | 08/02/2018 |
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/02/2015 |
Taligen Therapeutics, Inc.
 Taligen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Taligen Therapeutics is a biotechnology company pioneering a new approach to treating inflammatory and immune diseases by regulating the complement system, a potent and ubiquitous immune pathway. Based on new insights and unique proprietary technology related to complement biology, Taligen is building a deep product candidate pipeline of novel protein therapeutics which selectively identify, target and concentrate on inflammatory tissues. Taligen's targeted drugs have been shown to naturally and broadly control aberrant inflammation in a broad array of genetic, orphan and large market diseases. Founded in 2004, Taligen Therapeutics maintains its headquarters in Cambridge, Massachusetts. | Chief Tech/Sci/R&D Officer | 24/02/2012 |
Wyeth Corp.
 Wyeth Corp. Pharmaceuticals: MajorHealth Technology Wyeth LLC develops, manufactures, and distributes pharmaceuticals and biological substances. The company was founded in 1926 and is headquartered in Madison, NJ. | Chief Tech/Sci/R&D Officer | - |
Antisoma, Inc.
 Antisoma, Inc. Pharmaceuticals: MajorHealth Technology Antisoma, Inc. develops drugs and pharmaceuticals. The firm's products include Xanafide, Symadex, and Clomet. Its products are used in clinical and preclinical development for multiple cancer indications. The company was founded in 2001 and is headquartered Cambridge, MA. | Corporate Officer/Principal | - |
Formation de Bill Lundberg
| Massachusetts Institute of Technology | Undergraduate Degree |
| University of Massachusetts | Masters Business Admin |
| Stanford University School of Medicine | Doctorate Degree |
| The Isenberg School of Management | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| MERUS N.V. | Health Technology |
| CRISPR THERAPEUTICS AG | Health Technology |
| VOR BIOPHARMA INC. | Health Technology |
| Entreprise privées | 9 |
|---|---|
Wyeth Corp.
Wyeth Corp. Pharmaceuticals: MajorHealth Technology Wyeth LLC develops, manufactures, and distributes pharmaceuticals and biological substances. The company was founded in 1926 and is headquartered in Madison, NJ. | Health Technology |
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
| Antisoma Research Ltd. | |
Taligen Therapeutics, Inc.
Taligen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Taligen Therapeutics is a biotechnology company pioneering a new approach to treating inflammatory and immune diseases by regulating the complement system, a potent and ubiquitous immune pathway. Based on new insights and unique proprietary technology related to complement biology, Taligen is building a deep product candidate pipeline of novel protein therapeutics which selectively identify, target and concentrate on inflammatory tissues. Taligen's targeted drugs have been shown to naturally and broadly control aberrant inflammation in a broad array of genetic, orphan and large market diseases. Founded in 2004, Taligen Therapeutics maintains its headquarters in Cambridge, Massachusetts. | Health Technology |
Sarossa Capital Ltd.
 Sarossa Capital Ltd. Financial ConglomeratesFinance Sarossa Capital Ltd. is an investment holding and management company. Its principal activity is investing in and growth and development of businesses which present opportunities for value creations. The company currently intends to indentify investment opportunities offering the potential to deliver a favorable return to shareholders over the medium term, primarily in the form of capital gain. The company was founded in 1988 and is headquartered in London, the United Kingdom. | Finance |
Antisoma, Inc.
Antisoma, Inc. Pharmaceuticals: MajorHealth Technology Antisoma, Inc. develops drugs and pharmaceuticals. The firm's products include Xanafide, Symadex, and Clomet. Its products are used in clinical and preclinical development for multiple cancer indications. The company was founded in 2001 and is headquartered Cambridge, MA. | Health Technology |
Alliance for Regenerative Medicine
 Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Health Services |
Q32 Bio, Inc.
Q32 Bio, Inc. BiotechnologyHealth Technology Q32 Bio develops immunomodulatory therapies with protein based molecules using a platform. The company was founded by Shelia Violette and is headquartered in Cambridge, MA. | Health Technology |
